- 學位論文
大腸直腸癌K-ras突變基因影響臨床預後之機轉研究
K-ras mutation gene affect the prognosis of colorectal cancer via the over-expression of ribonucleotide reductase M2
摘要
研究背景:在台灣地區，大腸直腸癌(Colorectal cancer, CRC)位居癌症死亡原因的第三位，且自2008年起其發生率一直居所有癌症中的第一位。在新診斷的病例中，約有20-25%的患者為疾病晚期，併有遠處轉移，即使在接受治癒性切除後，約30%的晚期CRC患者仍會復發， Normanno ( 2009)證實，k-ras基因突變與轉移性CRC患者的標靶治療抗藥性有關，而k-ras基因會誘導核醣核苷酸還原酶M2(ribonucleotide reductase M2, RRM2)的表現，因此RRM2和p53R2的表現與腫瘤惡性程度及數種癌症的進展可能有關。本研究目的在確定p53R2 / RRM2與上游之miR-211表現、p53、APC和k-ras基因狀態與CRC患者臨床結果的關係。 研究方法:本研究共收集192個大腸直腸癌腫瘤組織樣本，利用免疫組織化學染色法及DNA直接定序法分析腫瘤組織中的p53R2/ RRM2蛋白表現及p53/APC/k-ras基因突變，並透過即時定量聚合酶鏈鎖反應(real-time polymerase chain reaction)檢測miR-211的表現量。 研究結果:結果發現相較於無淋巴結及遠處轉移的早期CRC患者，有淋巴結轉移及遠處轉移的晚期CRC患者出現較低量的p53R2表現及較高量的RRM2表現。RRM2的高量表現與CRC患者的整體存活期(overall survival, OS)及無病生存期(disease-free survival, DFS)呈負相關。腫瘤組織中的RRM2高表現與k-ras基因突變有關。CRC患者腫瘤組織中RRM2的表現與上游的miR-211呈負相關，且miR-211的表現與k-ras突變患者的存活與腫瘤復發相關。 結論:根據上述研究成果推測CRC患者腫瘤組織中miR-211的調降和RRM2的過度表現可用於預測腫瘤轉移和疾病預後，特別是對有k-ras基因突變的患者。
並列摘要
Background: Colorectal cancer (CRC) ranks as the third-leading cause of cancer-related deaths in Taiwan. The expression of ribonucleotide reductase M2 (RRM2) and p53R2 is correlated with tumoral malignancy and progression in several types of cancer. Methods: The aim of this study was to determine the association of p53R2/RRM2 with upstream expression of miR-211 and the association of expression levels of p53, APC, and k-ras with clinical outcomes in CRC patients. The study consisted of 192 tumor tissue samples obtained from CRC patients. Immunohistochemistry and DNA direct sequencing were performed to analyze p53R2/RRM2 protein expression and p53/APC/k-ras gene mutations in these samples. The expression level of miR-211 was detected by the real-time polymerase chain reaction (PCR). Results: The results showed that the expression of p53R2 was lower and that of RRM2 was higher in patients with lymph node metastasis, distant metastasis, and late-stage CRC as compared to patients without lymph node metastasis, distant metastasis, and early-stage CRC. High expression of RRM2 in patients had a negative impact on overall survival (OS) and disease-free survival (DFS) in CRC. The expression of RRM2 in tumor tissues was positive and correlated with that of the k-ras gene mutation. Upstream miR-211 expression was negatively correlated with RRM2 expression in tumor tissues of CRC patients, and it was correlated with patient survival and tumoral recurrence in patients with k-ras mutations. Conclusion: We suggest that downregulation of miR-211 and overexpression of RRM2 in tumor tissues of CRC patients could be used to predict metastases and disease prognosis, especially in patients with k-ras gene mutations.
參考文獻
延伸閱讀
- Kuo, Y. H., Huang, C. Y., Chen, C. J., Hsu, H. C., Chuang, H. C., Lee, T. H., Hsieh, M. C., Huang, W. S., & Chin, C. C. (2017). 在發生遠端轉移的結直腸癌患者，存有KRAS突變對第二線Oxaliplatin (FOLFOX-6) 的治療影響. 中華民國大腸直腸外科醫學會雜誌, 28(1), 34-42. https://doi.org/10.6312/SCRSTW.2017.28(1).10528
- Chang, T. K., Tsai, H. L., Su, W. C., Huang, C. W., Yeh, Y. S., & Wang, J. Y. (2018). KRAS基因突變於接受regorafenib及FOLFIRI為救援治療的轉移性大腸直腸癌病人. 中華民國大腸直腸外科醫學會雜誌, 29(1), 35-44. https://doi.org/10.6312/SCRSTW.2018.29(1).10623
- Chang, T. K. (2018). KRAS基因突變於接受regorafenib及FOLFIRI為救援治療的轉移性大腸直腸癌病人 [master's thesis, Kaohsiung Medical University]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0011-2306201817235200
- 陳泓仁（2020）。建立殺手細胞免疫球蛋白樣受體(KIR)基因鑑定平臺以及大腸直腸癌患者之KIR基因型分析〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU202003490
- 莊雅如（2011）。The - 819 C / T Single nucleotide polymorphism of Interleukin - 10 gene is associated to Onset of Colorectal Cancer〔碩士論文，中山醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0003-2208201101380000